Condylox — Medicare Part D Spending

Generic: Podofilox | Manufacturer: Overall

2023 Spending

$16.6K

2023 Claims

2023 Beneficiaries

Cost/Unit (2023)

$189.69

5-Year Spending Trend (2019-2023)

Year	Total Spending	Claims	Beneficiaries	Cost/Unit
2019	$497.9K	650	444	$182.88
2020	$410.8K	583	422	$183.41
2021	$421.9K	561	406	$184.87
2022	$308.4K	440	348	$185.89
2023	$16.6K	25	25	$189.69

5Y CAGR (cost/unit): 0.9%YoY Change (2022-2023): 2.0%

📊

DrugPricePeek Editorial TeamData Specialists

The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.

✓ Sourced from CMS NADAC & Medicare Part D✓ Quarterly review✓ No paid placements

Read our full methodology or contact us with corrections.

Frequently Asked Questions

How much does Medicare spend on Condylox?

In 2023, Medicare Part D spent $16.6K on Condylox (Podofilox), serving 25 beneficiaries across 25 claims.

What is the cost per unit of Condylox under Medicare?

The weighted average cost per dosage unit of Condylox was $189.69 in 2023. The 5-year compound annual growth rate (2019-2023) was 0.9%.

Who manufactures Condylox?

Condylox (generic name: Podofilox) is manufactured by Overall. There are 1 manufacturer(s) listed in the CMS database for this drug.

Is Condylox covered by Medicare Part D?

Yes, Condylox is included in Medicare Part D spending data, indicating it is covered by Part D plans. However, specific coverage and tier placement vary by plan. Check with your specific Part D plan for formulary details.

Where does this Medicare spending data come from?

All Medicare Part D spending data comes from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Spending by Drug dataset, which is publicly available at data.cms.gov.

Explore More Data Tools

For adjacent public-data tools, methodology notes, and network updates, visit DataPeek Facts.